Alterity Therapeutics Announced Late Tuesday It Received A A$4.74M Research & Development Tax Incentive Refund
Portfolio Pulse from Charles Gross
Alterity Therapeutics Limited has received a A$4.74 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive Scheme. The refund is related to the cost of eligible research and development activities conducted during the financial year ended 30 June 2022. The funds will be used to further Alterity’s clinical development and research activities, including the ongoing Phase 2 clinical trials for the Company’s lead drug candidate ATH434 in Multiple System Atrophy.
August 15, 2023 | 8:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alterity Therapeutics has received a significant cash refund which will be used to fund its ongoing research and development activities. This could potentially accelerate the development of its lead drug candidate, potentially leading to positive future outcomes.
The cash refund received by Alterity Therapeutics is a significant boost to its financial resources. This will allow the company to invest more in its research and development activities, particularly in the development of its lead drug candidate. This could potentially lead to positive outcomes in the future, such as successful clinical trials and eventual drug approval, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100